ISMP has identified possible safety issues with Paxlovid, which was recently authorized for the treatment of COVID-19. Tablets need to be removed from the blister pack for patients with moderate renal impairment. For a copy of ISMP’s special alert with safe practice recommendations, visit: https://www.ismp.org/node/29033